Growth Metrics

Merck (MRK) Free Cash Flow Growth (3y) (2012 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FCF Growth (3y) (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - 27.23%
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 41.47%
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn -15.10%
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn -3.92%
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn 106.58%
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 27.06%
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 14.07%
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn 210.20%
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn -34.49%
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 106.58%
Dec 31, 2025 -17.77%
Sep 30, 2025 15.16%
Jun 30, 2025 -7.28%
Mar 31, 2025 -32.30%
Dec 31, 2024 -13.53%
Sep 30, 2024 32.89%
Jun 30, 2024 69.00%
Mar 31, 2024 141.63%
Dec 31, 2023 -33.43%
Sep 30, 2023 74.62%
Jun 30, 2023 26.56%
Mar 31, 2023 47.21%
Dec 31, 2022 82.99%
Sep 30, 2022 11.07%
Jun 30, 2022 11.29%
Mar 31, 2022 72.10%
Dec 31, 2021 13.44%
Sep 30, 2021 19.21%
Jun 30, 2021 -28.95%
Mar 31, 2021 -39.26%
Dec 31, 2020 -15.70%
Sep 30, 2020 40.85%
Jun 30, 2020 -22.69%
Mar 31, 2020 -73.96%
Dec 31, 2019 -31.19%
Sep 30, 2019 8.44%
Jun 30, 2019 23.40%
Mar 31, 2019 -26.86%
Dec 31, 2018 -10.81%
Sep 30, 2018 -10.60%
Jun 30, 2018 4.88%
Mar 31, 2018 -30.29%
Dec 31, 2017 60.91%
Sep 30, 2017 -33.89%
Jun 30, 2017 13.25%
Mar 31, 2017 -26.51%
Dec 31, 2016 5.86%
Sep 30, 2016 -10.67%
Jun 30, 2016 -13.99%
Mar 31, 2016 -1.63%
Dec 31, 2015 53.83%
Sep 30, 2015 3.20%
Jun 30, 2015 -0.85%
Mar 31, 2015 4.51%
Dec 31, 2014 -37.15%
Sep 30, 2014 -0.96%
Jun 30, 2014 -6.81%
Mar 31, 2014 15.56%
Dec 31, 2013 -3.38%
Sep 30, 2013 16.83%
Jun 30, 2013 -13.63%
Mar 31, 2013 24.83%
Dec 31, 2012 -15.11%
Sep 30, 2012 85.93%
Jun 30, 2012 86.48%
Mar 31, 2012 56.29%